Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary Financial performance for 9M 2024 (Growth numbers at constant exchange rates) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback